Recently published clinical trial demonstrated improved exercise tolerance and quality of life after EECP for patients with New York Heart Association class Ⅱ-Ⅲ heart failure (average ejection fraction of 23%) secondary to ischemic or dilated cardiomyopathy.There were no significant adverse events reported.Furthermore,data from the Internationai EECP Patient Registry show that that patients with reduced left ventricular function (< 35%) achieved similar reductions in angina as those with preserved ejection fraction.The cost is currently estimatedto be US$5000-$7000 for a 35-treatment session.However,if found to be effective and safe,EECP could result in an enormous cost savings by reducing the amount of medication patients require and the occurrence of adverse events secondary to medication interactions that often result in hospital admissions.